Phase II Study of Eribulin plus Pembrolizumab in Metastatic Soft Tissue Sarcomas: Clinical Outcomes and Biological Correlates.
Candace L HaddoxMichael J NathensonEmanuele MazzolaJia-Ren LinJoanna BaginskaAllison N NauJason L WeiratherEdwin ChoyAdrian Mariño-EnriquezJeffrey A MorganGregory M CotePriscilla A MerriamAndrew J WagnerPeter Karl SorgerSandro SantagataSuzanne GeorgePublished in: Clinical cancer research : an official journal of the American Association for Cancer Research (2024)
The combination of eribulin and pembrolizumab demonstrated promising activity in LPS and angiosarcoma.
Keyphrases
- phase ii study
- metastatic breast cancer
- soft tissue
- open label
- phase ii
- advanced non small cell lung cancer
- locally advanced
- squamous cell carcinoma
- small cell lung cancer
- placebo controlled
- inflammatory response
- clinical trial
- anti inflammatory
- phase iii
- epidermal growth factor receptor
- randomized controlled trial
- study protocol
- radiation therapy
- double blind